We revealed that TPBCs may have different driver events from ER-PR-HER2+ breast cancers, including a lower TP53 mutation rate, a lower ERBB2 amplification rate and a higher CCND1 amplification rate. This evidence concerns the gene PGR and breast carcinoma.